China News Network, Shanghai, March 23 (Chen Jing Wang Guangzhao) Reporter learned on the 23rd that a research results of Chinese medical experts confirmed that a non -invasive diagnostic product based on urine tumor DNA can effectively detect urinary epithelial cancer in the early stage. OverallThe diagnostic sensitivity reaches 91.37%, which can effectively increase the early discovery rate of urinary epithelial cancer.
The new issue of the authoritative academic journal Molecular Cancer (“Molecular Tumor”) published this achievement led by Professor Ye Dingwei’s team of Professor Ye Dingwei, auxiliary oncology hospital affiliated to Fudan University.It is reported that urothelial carcinoma (UC) is one of the most common urinary tumors and occurs in the pelvis, ureter and bladder.
”Clinically, about a quarter of the patients with urinary tract epidermal cancer are already in the middle and late stages at the initial diagnosis.The five -year survival rate of patients will exceed 90%; once muscle layer infiltration or metastasis occurs, the patient’s survival and quality of life have decreased significantly, and the five -year survival rate of patients in advanced stage is less than 10%.
According to reports, cystoscopy or ureteroscopy combined with pathological biopsy is the “gold standard” currently diagnosed with urinary epithelial cancer.However, this method of examination is an invasive surgery, and the patient’s compliance is relatively low.Some currently approved urine -based urinary diagnosis methods, such as urine falling cell examination, FISH and NMP22, etc., there are low sensitivity (especially for low -grade tumor and upper urinary epithelial cancer), poor accuracy, etc.question.
Professor Ye Dingwei said that clinically urgently need a non -invasive, convenient, and accurate urinary epithelial cancer detection tool to supplement the current early diagnostic strategies of urinary epithelial cancer to effectively increase the early diagnostic ratio of urinary epithelial cancer, thereby increasing patients with patientsThe overall effect.
In order to optimize the early diagnostic strategy of urinary epithelial cancer, Professor Ye Dingwei team led by Professor Ye Dingwei, and the team of the First Hospital of Peking University, the Second Hospital of Tianjin Medical University, and the relevant biotechnology Co., Ltd. developed a urine -based DNA (UTDNA)Urotic carcinoma non -invasive diagnostic products (UI SEEK), and conduct verification of forward -looking clinical studies nationwide.
